Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19

Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy....

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Annsea, Iwasaki, Akiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255347/
https://www.ncbi.nlm.nih.gov/pubmed/32464097
http://dx.doi.org/10.1016/j.chom.2020.05.008
_version_ 1783539719732199424
author Park, Annsea
Iwasaki, Akiko
author_facet Park, Annsea
Iwasaki, Akiko
author_sort Park, Annsea
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.
format Online
Article
Text
id pubmed-7255347
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-72553472020-05-28 Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19 Park, Annsea Iwasaki, Akiko Cell Host Microbe Article Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19. Elsevier Inc. 2020-06-10 2020-05-27 /pmc/articles/PMC7255347/ /pubmed/32464097 http://dx.doi.org/10.1016/j.chom.2020.05.008 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Park, Annsea
Iwasaki, Akiko
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
title Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
title_full Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
title_fullStr Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
title_full_unstemmed Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
title_short Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
title_sort type i and type iii interferons – induction, signaling, evasion, and application to combat covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255347/
https://www.ncbi.nlm.nih.gov/pubmed/32464097
http://dx.doi.org/10.1016/j.chom.2020.05.008
work_keys_str_mv AT parkannsea typeiandtypeiiiinterferonsinductionsignalingevasionandapplicationtocombatcovid19
AT iwasakiakiko typeiandtypeiiiinterferonsinductionsignalingevasionandapplicationtocombatcovid19

Ejemplares similares